

Ovarian Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/O61F1485E56EN.html>

Date: June 2020

Pages: 3802

Price: US\$ 2,500.00 (Single User License)

ID: O61F1485E56EN

Abstracts

Ovarian Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2020, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical,

Discovery and Unknown stages are 2, 25, 189, 202, 3, 21, 285, 50 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 17, 15, 54 and 11 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Ovarian Cancer - Overview

Ovarian Cancer - Therapeutics Development

Ovarian Cancer - Therapeutics Assessment

Ovarian Cancer - Companies Involved in Therapeutics Development

Ovarian Cancer - Drug Profiles

Ovarian Cancer - Dormant Projects

Ovarian Cancer - Discontinued Products

Ovarian Cancer - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Ovarian Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Ovarian Cancer - Pipeline by 4D Pharma Plc, H1 2020
Ovarian Cancer - Pipeline by 4SC AG, H1 2020
Ovarian Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
Ovarian Cancer - Pipeline by AB Science SA, H1 2020
Ovarian Cancer - Pipeline by AbbVie Inc, H1 2020
Ovarian Cancer - Pipeline by AbClon Inc, H1 2020
Ovarian Cancer - Pipeline by Abion Inc, H1 2020
Ovarian Cancer - Pipeline by ABL Bio Inc, H1 2020
Ovarian Cancer - Pipeline by ABM Therapeutics Inc, H1 2020
Ovarian Cancer - Pipeline by Acepodia Biotech Inc, H1 2020
Ovarian Cancer - Pipeline by Acrotech Biopharma LLC, H1 2020
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
Ovarian Cancer - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Ovarian Cancer - Pipeline by ADC Therapeutics SA, H1 2020
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020
Ovarian Cancer - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Ovarian Cancer - Pipeline by ADRx Inc, H1 2020
Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2020
Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
Ovarian Cancer - Pipeline by Adze Biotechnology Inc, H1 2020
Ovarian Cancer - Pipeline by Affimed GmbH, H1 2020
Ovarian Cancer - Pipeline by Affina Biotechnologies Inc, H1 2020
Ovarian Cancer - Pipeline by Agency for Science, Technology and Research, H1 2020

Ovarian Cancer - Pipeline by Agenus Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Ovarian Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
4SC AG
Aadi Bioscience Inc
AB Science SA
AbbVie Inc
AbClon Inc
Abion Inc
ABL Bio Inc
ABM Therapeutics Inc
Acepodia Biotech Inc
Acrotech Biopharma LLC
Adaptimmune Therapeutics Plc
Adare Pharmaceuticals Inc
ADC Therapeutics SA
Adgero Biopharmaceuticals Holdings Inc
Adlai Nortye Biopharma Co Ltd
ADRx Inc
Advanced Cancer Therapeutics LLC
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH

Affina Biotechnologies Inc
Agency for Science, Technology and Research
Agenus Inc
AIM ImmunoTech Inc
AiVita Biomedical Inc
Aldeyra Therapeutics Inc
Alfasigma SpA
Alkermes Plc
Allife Medical Science and Technology Co Ltd
Alligator Bioscience AB
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
Alteogen Inc
ALX Oncology Inc
Ambrx Inc
Amgen Inc
Amplia Therapeutics Ltd
Anew Oncology Inc
AnGes Inc
Angex Pharmaceutical Inc
Anixa Biosciences Inc
ANP Technologies Inc
AntiCancer Inc
Anwita Biosciences Inc
AP Biosciences Inc
Apexian Pharmaceuticals Inc
Apexigen Inc
Aphios Corp
Apollomics Inc
Apotex Inc
Aprea Therapeutics AB
Aprogen Inc
Aravive Inc
Arch Oncology Inc
Arcus Biosciences Inc
Argenx SE
Arrien Pharmaceuticals LLC
Asana BioSciences LLC
Ascenta Therapeutics Inc

Ascentage Pharma Group International
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
Atreca Inc
Atrin Pharmaceuticals LLC
Aurigene Discovery Technologies Ltd
Avicanna Inc
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BBS NanoTechnology Ltd
BeiGene Ltd
Beijing Fogangren Bio-Pharm Tech Co Ltd
Beijing Foreland Pharma Co Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioAtla LLC
BIOCND Inc
BioEclipse Therapeutics Inc
BioIntegrator Ltd
Biokine Therapeutics Ltd
BioMed Valley Discoveries Inc
BioMoti Ltd
BioNTech SE
BioVaxys LLC
bluebird bio Inc
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Byondis BV
Canget BioTekpharma LLC
Cardiff Oncology Inc
Carisma Therapeutics Inc

Carlina Technologies SAS
CaroGen Corp
Carrick Therapeutics Ltd
Carrick Therapeutics UK Ltd
Cartherics Pty Ltd
CAS-Lamvac Biotech Co Ltd
Cellatoz Therapeutics Inc
Celldex Therapeutics Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cello Therapeutics Inc
Celprogen Inc
Celsion Corp
Celtec Inc
Celyad Oncology
Centurion BioPharma Corp
CerRx Inc
CG Oncology Inc
CHA Biotech Co Ltd
Checkmate Pharmaceuticals Inc
Chipscreen Biosciences Ltd
Chongqing Pharmaceutical Research Institute Co Ltd
Clarity Pharmaceuticals Pty Ltd
Claudin Technologies LLC
Clayton Biotechnologies Inc
Cloaked Therapeutics LLC
Clovis Oncology Inc
CMG Pharmaceutical Co Ltd
CNS Pharmaceuticals Inc
CohBar Inc
Coherent Biopharma
Commence Bio Inc
Compugen Ltd
Context Therapeutics LLC
Convert Pharmaceuticals SA
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
Cue Biopharma Inc

CureLab Oncology Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
Cynvec LLC
Cyteir Therapeutics Inc
Cytocom Inc
Cytodyn Inc
CZ BioMed Corp
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DC Prime BV
Deciphera Pharmaceuticals Inc
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Delta-Fly Pharma Inc
DevaCell Inc
Disulfican Ltd
Dongkook Pharmaceutical Co Ltd
Dophen Biomed Inc
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Elicio Therapeutics
Ellipses Pharma Ltd
Elthera AG
Elucida Oncology Inc
ENB Therapeutics LLC
EntreChem SL
EpicentRx Inc
Epigen Biosciences Inc
Epigene Therapeutics Inc
Epizyme Inc
Epsilogen Ltd
Epygen Biotech Pvt Ltd
Ervaxx Ltd
Esperance Pharmaceuticals Inc
Esperas Pharma Inc

Essential Biotechnology LLC
Eureka Therapeutics Inc
Evestra Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Falcon Therapeutics Inc
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
For-Robin Inc
Fujifilm Holdings Corp
GAiA BioMedicine Inc
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genekey Biotech Chengdu Co Ltd
Genelux Corp
Genentech Inc
Geneos Therapeutics Inc
Genisphere LLC
Genmab AS
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
Glycomantra Inc
GlycoNex Inc
Glysantis Inc
Gmax Biopharm Ltd
GO Therapeutics Inc
GP Pharm SA
Gracell Biotechnology Ltd
Gradalis Inc
GT Biopharma Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Hanghua Bio Pharmaceutical Technology Co
Hangzhou Neoantigen Therapeutics Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd

I would like to order

Product name: Ovarian Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/O61F1485E56EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O61F1485E56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970